BR112018016226A8 - Anticorpo antilipoarabinomanana (anti-lam) monoclonal humano, kit para detectar pelo menos um epítopo de lam, método para diagnosticar uma infecção de tuberculose ativa em um indivíduo, método para tratar uma infecção de tuberculose em um indivíduo, anticorpo monoclonal humano anti-lam e método de pré-concentração de lam a partir de uma amostra biológica - Google Patents

Anticorpo antilipoarabinomanana (anti-lam) monoclonal humano, kit para detectar pelo menos um epítopo de lam, método para diagnosticar uma infecção de tuberculose ativa em um indivíduo, método para tratar uma infecção de tuberculose em um indivíduo, anticorpo monoclonal humano anti-lam e método de pré-concentração de lam a partir de uma amostra biológica

Info

Publication number
BR112018016226A8
BR112018016226A8 BR112018016226A BR112018016226A BR112018016226A8 BR 112018016226 A8 BR112018016226 A8 BR 112018016226A8 BR 112018016226 A BR112018016226 A BR 112018016226A BR 112018016226 A BR112018016226 A BR 112018016226A BR 112018016226 A8 BR112018016226 A8 BR 112018016226A8
Authority
BR
Brazil
Prior art keywords
lam
individual
tuberculosis infection
antibody
human
Prior art date
Application number
BR112018016226A
Other languages
English (en)
Other versions
BR112018016226A2 (pt
Inventor
Abraham Pinter
Alok Choudhary
Deendayal Patel
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Publication of BR112018016226A2 publication Critical patent/BR112018016226A2/pt
Publication of BR112018016226A8 publication Critical patent/BR112018016226A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Abstract

a presente invenção fornece amplamente diferentes composições, kits, vetores e métodos que incluem anticorpos monoclonais direcionados aos epítopos encontrados dentro de lipoarabinomanana (lam) e fosfatidil-mio-inositol-manosídeo 6 (pim6) para o diagnóstico e tratamento de infecções de mycobacterium tuberculosis.
BR112018016226A 2016-02-10 2017-02-01 Anticorpo antilipoarabinomanana (anti-lam) monoclonal humano, kit para detectar pelo menos um epítopo de lam, método para diagnosticar uma infecção de tuberculose ativa em um indivíduo, método para tratar uma infecção de tuberculose em um indivíduo, anticorpo monoclonal humano anti-lam e método de pré-concentração de lam a partir de uma amostra biológica BR112018016226A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662293406P 2016-02-10 2016-02-10
PCT/US2017/016058 WO2017139153A1 (en) 2016-02-10 2017-02-01 Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Publications (2)

Publication Number Publication Date
BR112018016226A2 BR112018016226A2 (pt) 2019-01-02
BR112018016226A8 true BR112018016226A8 (pt) 2023-10-24

Family

ID=59563993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016226A BR112018016226A8 (pt) 2016-02-10 2017-02-01 Anticorpo antilipoarabinomanana (anti-lam) monoclonal humano, kit para detectar pelo menos um epítopo de lam, método para diagnosticar uma infecção de tuberculose ativa em um indivíduo, método para tratar uma infecção de tuberculose em um indivíduo, anticorpo monoclonal humano anti-lam e método de pré-concentração de lam a partir de uma amostra biológica

Country Status (10)

Country Link
US (3) US10729771B2 (pt)
EP (2) EP4299072A3 (pt)
JP (3) JP2019506412A (pt)
CN (2) CN110092830B (pt)
AU (1) AU2017218415A1 (pt)
BR (1) BR112018016226A8 (pt)
CA (1) CA3013904C (pt)
RU (1) RU2732502C2 (pt)
WO (1) WO2017139153A1 (pt)
ZA (2) ZA201805990B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10830760B2 (en) * 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity
WO2019186486A1 (en) * 2018-03-29 2019-10-03 Foundation Of Innovative New Diagnostics Antibody or antibody combination and method using same for detection of an antigen related to mycobacterium in a urine sample of a subject
WO2020018806A1 (en) * 2018-07-19 2020-01-23 Rutgers, The State University Of New Jersey Methods for dual detection and differentiation of infection by mycobactierum tuberculosis complex and nontuberculous mycobacteria
CN112639472A (zh) * 2018-08-31 2021-04-09 富士胶片株式会社 免疫层析试剂盒及结核菌的检测方法
JP7274595B2 (ja) 2019-09-30 2023-05-16 富士フイルム株式会社 イムノクロマトグラフィー
CN114341639A (zh) 2019-09-30 2022-04-12 富士胶片株式会社 免疫检查方法及浓缩用夹具
CN111337665A (zh) * 2020-01-16 2020-06-26 卢氏实验室公司 一种用于检测肺结核感染的免疫层析试纸条及其制备方法
EP4099017A4 (en) 2020-01-31 2023-02-15 FUJIFILM Corporation IMMUNOLOGICAL TEST METHOD
JP7350100B2 (ja) 2020-01-31 2023-09-25 富士フイルム株式会社 イムノクロマトグラフィー
WO2021152966A1 (ja) 2020-01-31 2021-08-05 富士フイルム株式会社 イムノクロマトグラフィー
CN111153992A (zh) * 2020-02-21 2020-05-15 首都医科大学附属北京胸科医院 结核分枝杆菌lam的单克隆抗体及其用途
WO2022011001A1 (en) * 2020-07-07 2022-01-13 The Regents Of The University Of California Method for antigen detection from direct clinical samples
EP4212873A1 (en) 2020-09-11 2023-07-19 FUJIFILM Corporation Concentration device, method for concentrating sample solution, method for testing sample solution, and test kit
EP4212876A4 (en) 2020-09-11 2024-02-28 Fujifilm Corp METHOD FOR CONCENTRATION OF LIQUID SAMPLES AND METHOD FOR INSPECTION OF LIQUID SAMPLES
CN116113826A (zh) 2020-09-11 2023-05-12 富士胶片株式会社 浓缩器件、被检体液的浓缩方法、被检体液的检查方法、及检查试剂盒
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
CN113480659B (zh) * 2021-06-30 2022-10-21 迪比康(上海)生物科技有限公司 人源抗结核分枝杆菌复合群lam单克隆抗体及其制备和应用
CN114984870A (zh) * 2022-03-15 2022-09-02 齐欣 一种重组蛋白质微球及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
DE69429820T3 (de) 1993-11-19 2013-02-28 Alkermes Controlled Therapeutics, Inc. Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US20010007660A1 (en) 1997-06-04 2001-07-12 Aharona Glatman-Freedman Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis
DE69811710T2 (de) 1997-11-07 2004-03-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
WO2002085335A1 (en) 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US7063725B2 (en) 2002-10-21 2006-06-20 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20050187631A1 (en) 2004-01-27 2005-08-25 Sdgi Holdings, Inc. Prosthetic device
US7335480B2 (en) * 2004-07-20 2008-02-26 Chemogen, Inc. Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same
CN101216491B (zh) * 2008-01-08 2012-06-06 广州益善生物技术有限公司 结核分枝杆菌检测液相芯片及其制备方法
US8999707B2 (en) * 2008-01-28 2015-04-07 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
WO2011013698A1 (ja) * 2009-07-29 2011-02-03 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
US9315566B2 (en) * 2011-01-24 2016-04-19 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2013129634A1 (ja) * 2012-02-29 2013-09-06 大塚製薬株式会社 抗リポアラビノマンナン抗体及び当該抗体を用いた抗酸菌症のイムノアッセイ
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Also Published As

Publication number Publication date
CN109073649A (zh) 2018-12-21
US20190038747A1 (en) 2019-02-07
US11707525B2 (en) 2023-07-25
US20200316199A1 (en) 2020-10-08
EP3414573B1 (en) 2023-11-08
JP2019506412A (ja) 2019-03-07
EP4299072A3 (en) 2024-05-01
JP2023075196A (ja) 2023-05-30
US11273220B2 (en) 2022-03-15
CA3013904C (en) 2023-12-12
EP4299072A2 (en) 2024-01-03
AU2017218415A1 (en) 2018-09-27
RU2018131622A (ru) 2020-03-10
US20220168420A1 (en) 2022-06-02
JP7316685B2 (ja) 2023-07-28
CN110092830B (zh) 2023-07-04
CN110092830A (zh) 2019-08-06
RU2732502C2 (ru) 2020-09-18
ZA201805990B (en) 2023-01-25
RU2018131622A3 (pt) 2020-04-13
CA3013904A1 (en) 2017-08-17
WO2017139153A1 (en) 2017-08-17
ZA202209045B (en) 2023-12-20
US10729771B2 (en) 2020-08-04
EP3414573A4 (en) 2019-10-30
EP3414573A1 (en) 2018-12-19
JP2021105034A (ja) 2021-07-26
BR112018016226A2 (pt) 2019-01-02

Similar Documents

Publication Publication Date Title
BR112018016226A8 (pt) Anticorpo antilipoarabinomanana (anti-lam) monoclonal humano, kit para detectar pelo menos um epítopo de lam, método para diagnosticar uma infecção de tuberculose ativa em um indivíduo, método para tratar uma infecção de tuberculose em um indivíduo, anticorpo monoclonal humano anti-lam e método de pré-concentração de lam a partir de uma amostra biológica
BR112019011186A2 (pt) conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
SV2019005807A (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
CL2018003407A1 (es) Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo.
ATE469656T1 (de) Verfahren und reagentien zur diagnose von hantavirusinfektionen
SG10201906750XA (en) Assays for detecting the presence or amount of an anti-drug antibody
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112018005812A2 (pt) ?método de imunoensaio para a detecção de um analito, kit de reagentes para detectar um analito por um imunoensaio e uso de um parceiro de ligação marcador-específico?
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
BR112019005167A2 (pt) método e kit para analisar uma amostra
BR112017021779A2 (pt) ?uma preparação combinada de anticorpos anti-staphylococcus aureus?
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
EA202191666A1 (ru) Антитела к il-27 и их применение
WO2017062496A3 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
UY37082A (es) Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv
BR112016017926A2 (pt) ensaio para detectar periostina humana
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
CL2021003367A1 (es) Anticuerpos anti-angpt2

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]